In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.

By S. C. Kim, Dong Wook Kim, Yong-Ho Shim, J. Bang, H. Oh, S. W. Kim, M. Seo. Journal of Controlled Release, 2001

675 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release (2010, methodology): “In preclinical in vivo studies with colon 26-bearing CDF1 mice, the AUC of NK105 was over 50 times higher, while the maximum plasma concentration (Cmax) in the tumors was three times higher compared to PTX (22).”
Block copolymer micelles: preparation, characterization and application in drug delivery. (2005, background): “Recently, a novel PEG-b-PDLLA injectable micelle formulation of paclitaxel called GenexolR showed a three-fold increase in the maximum tolerated dose (MTD), while providing much improved antitumor efficacy versus TaxolR in mice [101].”
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery (2006, background): “The in vivo antitumor efficacy of Genexol-PM was also found to be greater than that of taxol (47).”
Strategies to Address Low Drug Solubility in Discovery and Development (2013, background): “Compared with Taxol, the maximum tolerable dose of Genexol in mice is three times higher (Kim et al., 2001).”
Role of nanotechnology in targeted drug delivery and imaging: a concise review. (2005, background): “Polyester Preclinical Polyester degrades by hydrolysis to produce acid metabolites that in excess may not be desirable Paclitaxel [135] Doxorubicin [136,137]”